The Latest from OsoBio
It's been a busy spring at OsoBio. That means we have lots of news and updates to share with you.

First, we're pleased to announce we've been granted research and analytical licenses by the U.S. Drug Enforcement Administration (DEA) to handle Schedule II through V controlled substances.

Of course, we've long handled complex and potent products that require exacting attention and innovative solutions. We're now bringing this experience and expertise to the challenge of controlled substances.

Browse the links here for more of our latest news. And be sure to visit our newly revamped website. We've made it easier for you to navigate and find the information you need. Email Milton Boyer and let us know what you think!

As always, we appreciate the trust you place in us as a manufacturing partner. Please let us know if we can offer any assistance to you in the coming months.
The DEA recently approved OsoBio's registration requests to research, analyze and manufacture Class II-V substances – making us one of the few injectable CMOs in the United States capable of delivering controlled drugs. Read more about these services here.
Incorporating controlled substances into OsoBio's capabilities was made possible because of our experience working with highly potent products. If you have challenging products, learn more about how we can help.
Capability questions?
Need a reminder of what services and capabilities OsoBio can offer? Want to learn more about planned operational improvements? Craig Mastenbaum or Bob Cashman will be glad to update you.
Quick Links
We’re excited to share our new, improved website with you! As always, we appreciate your comments and suggestions for improvement.
OsoBio was honored recently for its efforts to protect water quality in the Rio Grande River. Learn more here.
Sue Schniepp, vice president of quality at OsoBio, examines in her June PharmTech column why having a strong SOP isn't enough.
OsoBio's case study of the Risk-MaPP approach in multi-product parenteral facilities is again referenced in an article about Risk-MaPP and multi-use facilities in Contract Pharma.
OsoBio's Mike Marek, technical project manager, discusses increasingly complex biologic drug delivery technologies in the June issue of Contract Pharma magazine.
OSO BioPharmaceuticals (505) 923-2112

This email was sent to by OsoBio
4401 Alexander Boulevard, NE | | Albuquerque | NM | 87107
Forward to a friend | Manage Preferences | Unsubscribe